Treatment Options for Diabetes: An Update
|
|
- Ezra Fletcher
- 5 years ago
- Views:
Transcription
1 Treatment Options for Diabetes: An Update A/Prof. Marg McGill Manager, Diabetes Centre Dr. Ted Wu Staff Specialist Endocrinologist Diabetes Centre Centre of Health Professional Education Education Provider Please direct any program-related questions to:
2 Sponsors Proudly sponsored by: In collaboration with: Not so long ago...life was simple. Life is more complex now!
3 Diabetes medications in the past Tablets Metformin Sulfonylurea Insulin Short acting insulin Long acting insulin Diabetes medications now Tablets Metformin Sulfonylureas Thiazolidinediones Meglitinides -glucosidase inhibitors Incretin-based therapies DPP-4 inhibitors GLP-1 analogues Insulins Rapid acting analogues Short acting insulin Intermediate acting insulin Basal analogues Premixed insulins
4 Diabetes medications now Tablets Metformin Sulfonylureas Thiazolidinediones Meglitinides -glucosidase inhibitors Incretin-based therapies DPP-4 inhibitors GLP-1 analogues Insulins Rapid acting analogues Short acting insulin Intermediate acting insulin Basal analogues Premixed insulins Metformin - mechanisms Since 1970s (except US 1990s!) Mechanism of action: hepatic gluconeogenesis major effect insulin resistance minor effect Has greatest effect on fasting sugars HbA 1c by about 1-2% Weight neutral Does not cause hypos alone
5 Metformin Side effects GI upset common, but minor Nausea, Vomiting Diarrhoea, Cramping Taste disturbance Lactic acidosis very rare, but severe Only occurs if egfr <40 Dehydrated/fasting Contrast cardiac cath, radiology Metformin - usage Starting low, building up dose helps to decrease GI upset First line treatment in Type 2 Can also combine with almost any other tablet Can combine with insulin Can use in Type 1, esp later life Stop if egfr <30-40
6 Metformin Extended release Diabex XR Slow release formulation Take once a day, after dinner risk of GI upset 60-70% Sulfonylureas Since the 1960 s Stimulates insulin release from pancreas fasting and post-prandial sugars HbA 1c by about 1-2%
7 SU s Side Effects Hypos: Prolonged hypos Esp glibenclamide, glimepiride Weight gain Due to insulin Hypersensitivity sulfur allergy (in theory) Metallic taste SU s - Usage Usually second line, in combo with metformin Can combine with other tablets ( triple therapy ) or with insulin also Not useful in Type 1 or end stage Type 2 Requires some pancreas function
8 Meglitinides Glinides Repaglinide - NovoNorm now discontinued in Australia Not in Australia Nateglinide - Starlix Mitiglinide Glufast Relatively recent early 2000 s Meglitinides - Mechanisms Stimulates insulin release from pancreas Wt gain Shorter half life than SU s Supposedly more insulin release at meal times, less when fasting
9 Meglitinides Usage No real advantage over SU No fewer hypos fasting No better control after meals No better HbA 1c Can be used in place of SU e.g. allergy No longer available in Australia Thiozolidinediones Glitazones Troglitazone Rezulin No longer used due to liver toxicity Rosiglitazone Avandia Pioglitazone Actos Relatively recent late 1990 s
10 Glitazones - Mechanisms PPAR s (peroxisome proliferator-activated receptors) Nuclear receptors Glitazones activate the PPARs Rosiglitazone pure PPAR activation Pioglitazone mostly PPAR, some PPAR Increases insulin sensitivity Adipocyte differentiation Visceral fat subcut fat HbA 1c by about 1-1.5% Glitazones side effects Oedema Heart failure from oedema Wt gain Some oedema, some subcut fat Not bad weight Osteoporosis and fractures Possible CV disease Rosiglitazone (Avandia ) only NB. Pioglitazone decreases CV disease
11 Glitazones - Usage Third line agent Use in combination with metformin and SU Can use with insulin (pioglitazone only) Contraindicated: NYHA class III or IV heart failure -glucosidase inhibitors Acarbose Glucobay Not in Australia: Miglitol, Voglibose Late 1990s Inhibits -glucosidase in brush border of the small intestines Slows digestion of poly monosaccharides Slows absorption of CHO less rise in BSLs after meals
12 Acarbose Only affects post-prandial sugars Has no effect on fasting sugars No effect on insulin secretion No effect on insulin sensitivity HbA 1c by 0.5% Weight neutral Acarbose GIT upset Flatulence (almost 80%) Diarrhoea (15%) Dose related, therefore: Take just before meals Use lowest dose, and build up dose slowly Will not cause hypos by itself If hypos do occur (eg combo Rx), must use glucose as oral treatment Third line agent
13 Summary Oral hypoglycaemics Site of action of diabetic drugs: Pancreas Liver Muscle/Fat GI tract Sulfonylureas Metformin /- Acarbose Glitazones Glinides Diabetes medications now Tablets Metformin Sulfonylureas Thiazolidinediones Meglitinides -glucosidase inhibitors Incretin-based therapies DPP-4 inhibitors GLP-1 analogues Insulins Rapid acting analogues Short acting insulin Intermediate acting insulin Basal analogues Premixed insulins
14 Diabetes medications now Tablets Metformin Sulfonylureas Thiazolidinediones Meglitinides -glucosidase inhibitors Incretin-based therapies DPP-4 inhibitors GLP-1 analogues Insulins Rapid acting analogues Short acting insulin Intermediate acting insulin Basal analogues Premixed insulins What are Incretins? Incretins are GIT hormones: GLP-1 (glucagon-like peptide) GIP (glucose-dependent insulinotropic polypeptide) Both decreased in Type 2 Diabetes Novel target of diabetes treatment Incretin-based therapies: GLP-1 analogues DPP-4 inhibitors
15 Mode of action - Incretins Ingestion of food Glucose-dependent Insulin Muscle glucose uptake GI tract Incretin release GLP-1 & GIP β cells α cells Pancreas Glucose-dependent Glucagon Liver glucose production Glucose (fasting/prandial) Glucose-Dependent Effects of GLP-1 on Insulin Glucose mmol/l * * * * * GLP-1 Infusion * * *P<0.05 T2DM (N=10) Insulin pmol/l * * * * * 0 * * * When glucose levels approach normal values, insulin levels decrease. Nauck MA et al. Diabetologia 1993; 36: Placebo GLP-1
16 Glucose-Dependent Effect of GLP-1 on Glucagon Glucose mmol/l * * * * * GLP-1 Infusion * * Low risk of hypos *P<0.05 T2DM (N=10) Insulin Glucagon pmol/l pmol/l * * * * * 0 * * * Nauck MA et al. Diabetologia 1993; 36: * * * * Minutes When glucose levels approach normal values, insulin levels decrease. When glucose levels approach normal values, glucagon levels rebound. Placebo GLP-1 Incretins additional effects Insulin (glucose dependent) Glucagon (glucose dependent) Glucose Stomach emptying Central hunger signals Weight
17 Incretins GLP-1 Why not just inject GLP-1? Insulin Incretin GLP-1 Blood Glucose Glucagon Incretins GLP-1 Why not just inject GLP-1? Insulin GLP-1 broken down very quickly (1-2 min) By DPP-4 Incretin GLP-1 Glucagon Blood Glucose DPP-4
18 Getting around DPP-4 Native human GLP-1 Create GLP-1 analogues that are structurally resistant to DPP-4 97% amino acid homology to human GLP-1 1 Liraglutide Exenatide GLP-1 analogue Half-life Injection Frequency Liraglutide ~13 hrs Once-daily 1 53% amino acid homology to human GLP-1 2 Exenatide 2.4hrs Twice-daily 2 1. Liraglutide Product Information. 2. Exenatide Product Information. Getting around DPP-4 Exendin-4: From the Gila Monster Found to act like human GLP-1 Resistant to DPP-4 Longer half-life Twice-daily injections Exenatide (Byetta ) Dose: First of the GLP-1 analogues Many others to follow 5 10 g sci with food twice-daily Exenatide Product Information.
19 GLP-1 analogues Advantages: HbA 1c by % Weight 3 kg in 6 months 5 kg in 2 years Low risk of hypos if used alone or with metformin But can potentiate hypos if used with SU s Exenatide can be used as triple therapy under PBS 1. Liraglutide Product Information. 2. Exenatide Product Information. GLP-1 analogues Disadvantages: Injection working on daily/weekly dosing Nausea mild 15-30% severe 5% Pancreatitis Exenatide full authority PBS No combo with insulin under PBS Liraglutide registered with TGA, not currently on PBS 1. Liraglutide Product Information. 2. Exenatide Product Information.
20 Achieving a clinically relevant composite outcome of an HbA 1c of <7% without weight gain or hypoglycaemia 7 randomised, controlled, Phase III clinical trials were combined to facilitate a meta-analysis. The predefined composite endpoint (HbA 1c <7.0%, no weight gain, and no hypoglycaemic events) after 26 weeks of treatment was analysed by a logistic regression with previous treatment (combination or monotherapy) and randomised treatment as fixed effects and baseline values of HbA 1c and body weight as covariates. Zinman B et al. Diabetes Obes Metab 2011; 14: Getting around DPP-4 What if we block DPP-4? Insulin Incretin GLP-1 Blood Glucose Glucagon DPP-4
21 Getting around DPP-4 What if we block DPP-4? Insulin GLP-1 glucose Incretin GLP-1 Blood Glucose Glucagon DPP-4 Inhibitor DPP-4 DPP-4 Inhibitors Block DPP-4 action GLP-1 action Sitagliptin Januvia Vildagliptin Galvus Saxagliptin Onglyza Linagliptin Trajenta
22 DPP-4 Inhibitors Advantages: Effect is like GLP-1 analogues Less nausea than GLP-1 analogues HbA 1c % Weight neutral Can be take as tablet Combo tablets with metformin Sitagliptin approved for use in ESRD No known serious long term side effects DPP-4 Inhibitors Disadvantages: Depends on endogenous production of GLP-1 Already in Type 2 diabetes No weight loss Slight nasopharyngitis and URTIs Streamlined Authority PBS Dual therapy only under PBS No combo with insulin under PBS Some DPP-4 inhibitors have hepatic effects or restrictions in renal disease
23 DPP-4 Inhibitors - specifics Lowers HbA 1c Low risk of hypos with metformin Source: Respective full PI s, MIMS April 2012 No need to monitor LFTs Approved in End Stage Renal Disease Linagliptin (Trajenta ) Sitagliptin (Januvia ) Saxagliptin (Onglyza ) Vildagliptin (Galvus ) Sample T2DM treatment algorithm Pancreatic function Metformin SU Insulin GLP-1 DPP-4 Acarbose Pioglitazone *PBS = must withdraw DPP-4 or GLP-1 on initiation of next agent
24 Diabetes medications now Tablets Metformin Sulfonylureas Thiazolidinediones Meglitinides -glucosidase inhibitors Incretin-based therapies DPP-4 inhibitors GLP-1 analogues Insulins Rapid acting analogues Short acting insulin Intermediate acting insulin Basal analogues Premixed insulins Even more exotic agents coming Ultra-long basal insulins (e.g. degludec) Ultra-long GLP-1 analogues (e.g. liraglutide) GLP-1 + insulin combination (e.g. liraglutide + degludec) SGLT-2 inhibitors (e.g. dapaglifozin) Amylin analogues (e.g. pramlintide) Sirtuins
25 Summary Choice is a good thing! Tablets Metformin Sulfonylureas Thiazolidinediones Meglitinides -glucosidase inhibitors Incretin-based therapies DPP-4 inhibitors GLP-1 analogues Insulins Rapid acting analogues Short acting insulin Intermediate acting insulin Basal analogues Premixed insulin analogues
Glucose Control drug treatments
Glucose Control drug treatments It should be noted that glitazones are under suspicion of precipitating acute cardiac events and current recommendations contraindicate the use of glitazones in patients
More informationDrugs used in Diabetes. Dr Andrew Smith
Drugs used in Diabetes Dr Andrew Smith Plan Introduction Insulin Sensitising Drugs: Metformin Glitazones Insulin Secretagogues: Sulphonylureas Meglitinides Others: Acarbose Incretins Amylin Analogues Damaglifozin
More informationType 2 Diabetes Mellitus hypoglycaemic agents
Type 2 Diabetes Mellitus hypoglycaemic agents Name Metformin Drug Name (eg brand name) Metformin (Diaformin Diabex) Cost / PBS per 28d mth $10.24 (1.5g dly) 1000mg+500mg / $4.44+$5.80 Concerns? Lactic
More informationOral and Injectable Non-insulin Antihyperglycemic Agents
Appendix 5: Diabetes Education and Medical Management in Adults with Diabetes Oral and Injectable Non-insulin s This directive will be implemented by RPhs, RNs or RDs who have been deemed authorized implementers.
More informationNewer Drugs in the Management of Type 2 Diabetes Mellitus
Newer Drugs in the Management of Type 2 Diabetes Mellitus Dr. C. Dinesh M. Naidu Professor of Pharmacology, Kamineni Institute of Medical Sciences, Narketpally. 1 Presentation Outline Introduction Pathogenesis
More informationManagement of Type 2 Diabetes
Management of Type 2 Diabetes Pathophysiology Insulin resistance and relative insulin deficiency/ defective secretion Not immune mediated No evidence of β cell destruction Increased risk with age, obesity
More informationYOU HAVE DIABETES. Angie O Connor Community Diabetes Nurse Specialist 25th September 2013
YOU HAVE DIABETES Angie O Connor Community Diabetes Nurse Specialist 25th September 2013 Predicated 2015 figures are already met 1 in 20 have diabetes:1in8 over 60years old Definite Diagnosis is key Early
More informationManagement of Type 2 Diabetes. Why Do We Bother to Achieve Good Control in DM2. Insulin Secretion. The Importance of BP and Glucose Control
Insulin Secretion Management of Type 2 Diabetes DG van Zyl Why Do We Bother to Achieve Good Control in DM2 % reduction 0-5 -10-15 -20-25 -30-35 -40 The Importance of BP and Glucose Control Effects of tight
More informationDIABETES. overview of pharmacologic agents used in the management of. Overview 4/3/2014 OBJECTIVES. Injectable Agents
overview of pharmacologic agents used in the management of DIABETES Kyle Roberts, Pharm.D. PGY-1 Pharmacy Resident Saint Alphonsus RMC 1. List the different classes of diabetes medications, including the
More informationMANAGEMENT OF TYPE 2 DIABETES
MANAGEMENT OF TYPE 2 DIABETES 3 Month trial of lifestyle changes. Refer to DESMOND structured education programme. Set glycaemic target HbA1c < 7.0% (53mmol/mol) or individualised If HbA1c > 53mmol/mol
More informationDiabetes Oral Agents Pharmacology. University of Hawai i Hilo Pre-Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D
Diabetes Oral Agents Pharmacology University of Hawai i Hilo Pre-Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D 1 Learning Objectives Understand the role of the utilization of free
More informationGLP-1 agonists. Ian Gallen Consultant Community Diabetologist Royal Berkshire Hospital Reading UK
GLP-1 agonists Ian Gallen Consultant Community Diabetologist Royal Berkshire Hospital Reading UK What do GLP-1 agonists do? Physiology of postprandial glucose regulation Meal ❶ ❷ Insulin Rising plasma
More informationWhat the Pill Looks Like. How it Works. Slows carbohydrate absorption. Reduces amount of sugar made by the liver. Increases release of insulin
Diabetes s Oral s - Pills These are some of the pills that are currently available in Canada to treat diabetes. Each medication has benefits and side effects you should be aware of. Your diabetes team
More informationDept of Diabetes Main Desk
Dept of Diabetes Main Desk 01202 448060 Glucose management in Type 2 Diabetes in Adults The natural history of type 2 diabetes is for HbA1c to deteriorate with time. A stepwise approach to treatment is
More informationWhat s New in Diabetes Treatment. Disclosures
What s New in Diabetes Treatment Shiri Levy M.D. Henry Ford Hospital Senior Staff Physician Service Chief, West Bloomfield Hospital Endocrinology, Metabolism, Bone and Mineral Disorders Disclosures None
More informationOral Medication for the Management of Diabetes Mechanism of. Duration of Daily Dosing Action
Glyburide (Micronase, Diabeta, Glynase) Glipizide (Glucotrol) Glipizide XL (Glucotrol XL) Glimepiride (Amaryl) Prandin (Repaglinide) Starlix (Nateglinide) 1.25, 2.5, 5mg tabs, Dosing: 2.5-20 mg 12- (Glynase:
More informationRPCC Pharmacy Forum. The Type 2 Diabetes Issue. Type 2 Diabetes: The Basics
Nov/Dec 2015 Issue 11 RPCC Pharmacy Forum Special Interest Articles: Diabetes Medication Chart Insulin Chart Afreeza Did you know? Exanatide, marketed as Byetta, is the synthetic form of exendin-4, which
More informationType 2 Diabetes: Where Do We Start with Treatment? DIABETES EDUCATION. Diabetes Mellitus: Complications and Co-Morbid Conditions
Diabetes Mellitus: Complications and Co-Morbid Conditions ADA Guidelines for Glycemic Control: 2016 Retinopathy Between 2005-2008, 28.5% of patients with diabetes 40 years and older diagnosed with diabetic
More informationDM Fundamentals Class 4 Meds for Type 2
DM Fundamentals Class 4 Meds for Type 2 Beverly Thomassian, RN, MPH, BC ADM, CDE President, Diabetes Education Services Copyright 1999 2015, Diabetes Education Services, All Rights Reserved. Diabetes Meds
More informationSociety for Ambulatory Anesthesia Consensus Statement on Perioperative Blood Glucose Management in Diabetic Patients Undergoing Ambulatory Surgery
Society for Ambulatory Anesthesia Consensus Statement on Perioperative Blood Glucose Management in Diabetic Patients Undergoing Ambulatory Surgery Girish P. Joshi, MB BS, MD, FFARCSI Anesthesia & Analgesia
More informationDM Fundamentals Class 4 Meds for Type 2
DM Fundamentals Class 4 Meds for Type 2 Beverly Thomassian, RN, MPH, BC ADM, CDE President, Diabetes Education Services Copyright 1999 2015, Diabetes Education Services, All Rights Reserved. Diabetes Meds
More informationType II Diabetes Improving Blood Sugar Control. Geneva Clark Briggs, Pharm.D., BCPS
Type II Diabetes Improving Blood Sugar Control Geneva Clark Briggs, Pharm.D., BCPS Overview Importance of glucose control State of control Review available therapies Helping patients achieve control The
More informationUpdate on Diabetes Mellitus
Update on Diabetes Mellitus Treatment: Targeting the Incretin System Overview Underlying defects with Type 2 diabetes Importance of managing postprandial glucose control Amylin Incretin Hormones New therapies
More informationNewer and Expensive treatment of diabetes. Endocrinology Visiting Associate Professor Institute of Medicine TUTH
Newer and Expensive treatment of diabetes Jyoti Bhattarai MD Endocrinology Visiting Associate Professor Institute of Medicine TUTH Four out of every five people with diabetes now live in developing countries.
More informationHow can we improve outcomes in Type 2 diabetes?
How can we improve outcomes in Type 2 diabetes? Earlier diagnosis Better patient education Stress central role of lifestyle management Identify and treat all risk factors Use rational pharmacological therapy
More informationNavigating the New Options for the Management of Type 2 Diabetes
Navigating the New Options for the Management of Type 2 Diabetes Clinical Associate Professor Mark Kennedy Department of General Practice, University of Melbourne Chair, Primary Care Diabetes Society of
More informationModulating the Incretin System: A New Therapeutic Strategy for Type 2 Diabetes. Overview. Prevalence of Overweight in the U.S.
Modulating the Incretin System: A New Therapeutic Strategy for Type 2 Diabetes Geneva Clark Briggs, PharmD, BCPS Overview Underlying defects with Type 2 diabetes Importance of managing postprandial glucose
More informationObjectives. Recognize all available medical treatment options for diabetes. Individualize treatment and glycemic target based on patient factors
No disclosure Objectives Recognize all available medical treatment options for diabetes Individualize treatment and glycemic target based on patient factors Should be able to switch to more affordable
More informationDisclosure. Learning Objectives. Case. Diabetes Update: Incretin Agents in Diabetes-When to Use Them? I have no disclosures to declare
Disclosure Diabetes Update: Incretin Agents in Diabetes-When to Use Them? I have no disclosures to declare Spring Therapeutics Update 2011 CSHP BC Branch Anar Dossa BScPharm Pharm D CDE April 20, 2011
More informationPharmacology Update for the Adult Patient - Newer Oral Medications for Diabetes
Pharmacology Update for the Adult Patient - Newer Oral Medications for Diabetes Brooke Hudspeth, PharmD, CDE, MLDE Director of Diabetes Prevention, Kroger Pharmacy Adjunct Assistant Professor, University
More informationA New Therapeutic Strategey for Type II Diabetes: Update 2008
Live, One Hour Webinar A New Therapeutic Strategey for Type II Diabetes: Update 2008 Geneva Clark Briggs, PharmD, BCPS Adjunct Professor at University of Appalachia College of Pharmacy in Grundy, Virginia.
More informationTREATMENTS FOR TYPE 2 DIABETES. Susan Henry Diabetes Specialist Nurse
TREATMENTS FOR TYPE 2 DIABETES Susan Henry Diabetes Specialist Nurse How can we improve outcomes in Type 2 diabetes? Earlier diagnosis Better patient education Stress central role of lifestyle management
More informationChief of Endocrinology East Orange General Hospital
Targeting the Incretins System: Can it Improve Our Ability to Treat Type 2 Diabetes? Darshi Sunderam, MD Darshi Sunderam, MD Chief of Endocrinology East Orange General Hospital Age-adjusted Percentage
More informationSitagliptin: first DPP-4 inhibitor to treat type 2 diabetes Steve Chaplin MSc, MRPharmS and Andrew Krentz MD, FRCP
Sitagliptin: first DPP-4 inhibitor to treat type 2 diabetes Steve Chaplin MSc, MRPharmS and Andrew Krentz MD, FRCP KEY POINTS sitagliptin (Januvia) is a DPP-4 inhibitor that blocks the breakdown of the
More informationObjectives. How Medicine Works to Control Blood Sugar Levels. What Happens When We Eat? What is diabetes? High Blood Glucose (Hyperglycemia)
How Medicine Works to Control Blood Sugar Levels Stacie Petersen, RN, CDE Objectives Define Diabetes List how medications work (ominous octet) Identify side effects of medications for diabetes What is
More informationNew Treatments for Type 2 diabetes. Nandini Seevaratnam April 2016 Rushcliffe Patient Forum
New Treatments for Type 2 diabetes Nandini Seevaratnam April 2016 Rushcliffe Patient Forum Overview Growing population of Type 2 diabetes Basic science on what goes wrong Current treatments Why there is
More informationFARXIGA (dapagliflozin) Jardiance (empagliflozin) tablets. Synjardy (empagliflozin and metformin hydrochloride) tablets. GLUCOPHAGE* (metformin)
Type 2 Medications Drug Class How It Works Brand and Generic Names Manufacturers Usual Starting Dose The kidneys filter sugar and either absorb it back into your body for energy or remove it through your
More informationVitamin D & Type 2 DM
Vitamin D & PTH Vitamin D & Type 2 DM Enhances insulion secretion Increases insulin release Promotes β-cell survival Reduces PTH Enhances insulin sensitivity RAS blockade Antiinflammatory Harinarayan Hormones
More informationModulating the Incretin System: A New Therapeutic Strategy for Type 2 Diabetes
Modulating the Incretin System: A New Therapeutic Strategy for Type 2 Diabetes Geneva Clark Briggs, PharmD, BCPS Adjunct Professor at University of Appalachia College of Pharmacy Clinical Associate, Medical
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Single Technology Appraisal. Canagliflozin in combination therapy for treating type 2 diabetes
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Single Technology Appraisal Canagliflozin in combination therapy for Final scope Remit/appraisal objective To appraise the clinical and cost effectiveness
More informationTable 1. Antihyperglycemic agents for use in type 2 diabetes
Table 1. Antihyperglycemic agents for use in type 2 diabetes DRUG IN ALPHA-GLUCOSIDASE INHIBITOR: inhibits pancreatic alpha-amyle and intestinal alpha-glucoside Acarbose (Glucobay) 0.6% Negligible Not
More informationINJECTABLE THERAPY FOR THE TREATMENT OF DIABETES
INJECTABLE THERAPY FOR THE TREATMENT OF DIABETES ARSHNA SANGHRAJKA DIABETES SPECIALIST PRESCRIBING PHARMACIST OBJECTIVES EXPLORE THE TYPES OF INSULIN AND INJECTABLE DIABETES TREATMENTS AND DEVICES AVAILABLE
More informationEarly treatment for patients with Type 2 Diabetes
Israel Society of Internal Medicine Kibutz Hagoshrim, June 22, 2012 Early treatment for patients with Type 2 Diabetes Eduard Montanya Hospital Universitari Bellvitge-IDIBELL CIBERDEM University of Barcelona
More informationWhat s New in Diabetes Medications. Jena Torpin, PharmD
What s New in Diabetes Medications Jena Torpin, PharmD 1 Objectives Discuss new medications in the management of diabetes Understand the mechanism of the medications discussed Understand the side effects
More informationDiabetes Medications: Oral Anti-Hyperglycemic Medications
Diabetes Medications: Oral Anti-Hyperglycemic Medications Medication Types 1. Biguanides 2. Sulfonylureas 3. Thiazolidinediones (TZDs) 4. Alpha-Glucosidase Inhibitors 5. D-Phenylalanine Meglitinides 6.
More informationSTEP 3: Add or Substitute with one of
Prescribing of Hypoglycaemic Agents for Adult Patients with Type 2 Diabetes: Sunderland Refer to DESMOND Structured Education classes to promote Increased Physical Activity, Weight Loss and Calories Reduction
More informationMultiple Small Feedings of the Mind: Diabetes. Sonja K Fredrickson, MD, BC-ADM March 7, 2014
Multiple Small Feedings of the Mind: Diabetes Sonja K Fredrickson, MD, BC-ADM March 7, 2014 Question 1: Setting A1c Goals Describe the evidence based approach to determining the target HgbA1c in different
More informationMr Rab Burtun. Dr David Kim. 8:30-10:30 WS #2: Diabetes Basic 11:00-13:00 WS #9: Diabetes Basic (Repeated)
Dr David Kim Endocrinologist and General Physician Waitemata DHB and Apollo Specialist Clinic Albany Auckland Mr Rab Burtun Diabetes Nurse Specialist Waitemata DHB Waitakere Hospital Auckland 8:30-10:30
More informationOptimal glucose control. DM Treatment. Glucose Control one out of many. Many guidelines: Confusing. Theorectically easy
DM Treatment How to Achieve Optimal Glycaemic Control The Tung Wah Eastern Hospital Experience of DM Share Care Experience Optimal glucose control Theorectically easy More challenging in the real world
More informationRole of incretins in the treatment of type 2 diabetes
Role of incretins in the treatment of type 2 diabetes Jens Juul Holst Department of Medical Physiology Panum Institute University of Copenhagen Denmark Diabetes & Obesity Spanish Society of Internal Medicine
More informationOverview T2DM medications. Winnie Ho
Overview T2DM medications Winnie Ho Diabetes in Australia 1.7 million Australians with diabetes, of these 85% have T2DM 2-fold excess risk CV death in patients with diabetes Risk factor for progression
More informationPractical Strategies for the Clinical Use of Incretin Mimetics CME/CE. CME/CE Released: 09/15/2009; Valid for credit through 09/15/2010
Practical Strategies for the Clinical Use of Incretin Mimetics CME/CE Robert R. Henry, MD Authors and Disclosures CME/CE Released: 09/15/2009; Valid for credit through 09/15/2010 Introduction Type 2 diabetes
More informationDIABETES. Mary Bruskewitz APNP, MS, BC-ADM Clinical Nurse Specialist Diabetes. November 2013
DIABETES Mary Bruskewitz APNP, MS, BC-ADM Clinical Nurse Specialist Diabetes November 2013 mbruskewitz@outlook.com Objectives Part 1 Overview of Endocrine Physiology Pathophysiology of Diabetes Diabetes
More informationGLP 1 agonists Winning the Losing Battle. Dr Bernard SAMIA. KCS Congress: Impact through collaboration
GLP 1 agonists Winning the Losing Battle Dr Bernard SAMIA KCS Congress: Impact through collaboration CONTACT: Tel. +254 735 833 803 Email: kcardiacs@gmail.com Web: www.kenyacardiacs.org Disclosures I have
More informationDrug Class Monograph
Drug Class Monograph Class: Dipeptidyl-Peptidase 4 (DPP-4) Inhibitors Drugs: alogliptin, alogliptin/metformin, Januvia (sitagliptin), Janumet (sitagliptin/metformin), Janumet XR (sitagliptin/metformin),
More informationSIMPLICITY IN T2DM MANAGEMENT WITH DPP4 INHIBITORS: SPECIAL POPULATION
SIMPLICITY IN T2DM MANAGEMENT WITH DPP4 INHIBITORS: SPECIAL POPULATION DR ROSE ZHAO-WEI TING ( 丁昭慧醫生 ) MBBS (HK), MRCP (UK), FHKCP, FHKAM (MEDICINE) Specialist in Endocrinology, Diabetes and Metabolism
More informationFebruary 2016 DIABETES PHARMACY TEAMS MAKE A DIFFERENCE. Why am I here? Why are you here? Identifying people at risk. What can we do?
DIABETES PHARMACY TEAMS MAKE A DIFFERENCE Sallianne Kavanagh MRPharmS, MSc, IP Lead Pharmacist Diabetes and Endocrinology Sheffield Teaching Hospitals UKCPA Joint Chair Diabetes and Endocrinology Why am
More informationDiabetes in the UK: Update on Diabetes Treatment and Care. Why is diabetes increasing? Obesity Increased waist circumference.
Update on Diabetes Treatment and Care Tahseen A Chowdhury Consultant Diabetologist Royal London and Mile End Hospitals Diabetes prevalence (thousands) Diabetes in the UK: 1995-21 3 25 2 15 1 5 Type 1 Type
More informationOral Agents. Ian Gallen Consultant Community Diabetologist Royal Berkshire Hospital Reading UK
Oral Agents Ian Gallen Consultant Community Diabetologist Royal Berkshire Hospital Reading UK What would your ideal diabetes drug do? Effective in lowering HbA1c No hypoglycaemia No effect on weight/ weight
More informationPRINCIPLES OF ORAL ANTIDIABETIC AND
07 PRINCIPLES OF ORAL ANTIDIABETIC AND INSULINOMIMETIC DRUG THERAPY Oral antidiabetic drugs (OADs) are being used in addition to lifestyle recommendations (MNT and physical activity) in type 2 diabetes.
More informationAlia Gilani Health Inequalities Pharmacist
Alia Gilani Health Inequalities Pharmacist THE SOUTH ASIAN HEALTH FOUNDATION (U.K.) (Registered Charity No. 1073178) 1. Case Study 2. Factors influencing prescribing 3. Special Considerations 4. Prescribing
More informationPancreatic b-cell Dysfunction in Type 2 Diabetes ZIAD KAHWASH, M.D. Insulin resistance: Defects in Insulin Signaling
Plasma insulin (mu/ml) ZIAD KAHWASH, M.D. resistance: Defects in Signaling Increased glucose production Glucose Insufficient glucose disposal X Liver glucagon insulin Pancreas Peripheral tissues (skeletal
More informationDrug Class Monograph
Class: Dipeptidyl-Peptidase 4 (DPP-4) Inhibitors Drug Class Monograph Drugs: alogliptin, Januvia (sitagliptin), Janumet (sitagliptin/metformin), Janumet XR (sitagliptin/metformin), Jentadueto (linagliptin/metformin),
More informationWhat s New in Type 2? Peter Hammond Consultant Physician Harrogate District Hospital
What s New in Type 2? Peter Hammond Consultant Physician Harrogate District Hospital Therapy considerations in T2DM Thiazoledinediones DPP IV inhibitors GLP 1 agonists Insulin Type Delivery Horizon scanning
More informationNon-Insulin Diabetes Medications Summary
Non-Insulin Diabetes Medications Summary Medications marked with an asterisk (*) can cause hypoglycemia INSULIN SECRETAGOGUES Sulfonylureas* GLYBURIDE* (Diabeta) (Micronase) production. Side effects: Potential
More informationWhat s New on the Horizon: Diabetes Medication Update
What s New on the Horizon: Diabetes Medication Update Outline of Talk Newly released and upcoming medications: the incretins, DPP-IV inhibitors, and what s coming Revised ADA/EASD and AACE guidelines:
More informationAntihyperglycemic Agents in Diabetes. Jamie Messenger, PharmD, CPP Department of Family Medicine East Carolina University August 18, 2014
Antihyperglycemic Agents in Diabetes Jamie Messenger, PharmD, CPP Department of Family Medicine East Carolina University August 18, 2014 Objectives Review 2014 ADA Standards of Medical Care in DM as they
More informationJulie White, MS Administrative Director Boston University School of Medicine Continuing Medical Education
MENTOR QI Diabetes Performance Improvement Initiative, Getting Patients to Goal in Glycemic Control: Current Data Julie White, MS Administrative Director Boston University School of Medicine Continuing
More informationPLEASE CHECK FULL SPECIFIC PRODUCT CHARACTERISTICS FOR MORE DETAILED AND CURRENT INFORMATION:
Metformin Standard tablets Modified-release tablets Metformin 1g sachets Metformin liquid 500mg/5ml (avoid use as expensive) < 2.00 5.32 for 56 tabs 500mg 13.16 for 60 sachets > 120 Ketoacidosis General
More informationGLP-1 Receptor Agonists and SGLT-2 Inhibitors. Debbie Hicks
GLP-1 Receptor Agonists and SGLT-2 Inhibitors Debbie Hicks Prescribing and Adverse Event reporting information is available at this meeting from the AstraZeneca representative The views expressed by the
More informationWhat s New on the Horizon: Diabetes Medication Update. Michael Shannon, MD Providence Endocrinology, Olympia WA
What s New on the Horizon: Diabetes Medication Update Michael Shannon, MD Providence Endocrinology, Olympia WA 1 Outline of Talk Newly released and upcoming medications: the incretins, DPP-IV inhibitors,
More informationPharmacologic Agents for Treatment of Type 2 Diabetes
Pharmacologic Agents for Treatment of Type 2 Diabetes SCAN Drugs Medication Biguanides 1 1 er uncoated tabs 500 mg & 750 mg Sulfonylureas 1 1 500 850 mg QD - TID 500 2000 mg glimepiride 1 1 1 8 mg glipizide
More informationOral Anti-diabetic Drugs in Older Adults with Diabetes
Oral Anti-diabetic Drugs in Older Adults with Diabetes Jae Min Lee Division of Endocrinology-Metabolism, Department of Internal Medicine, Eulji University Hospital, Eulji University School of Medicine,
More informationArrange 3 Monthly Review Re-enforce LIFESTYLE advice and check DRUG COMPLIANCE at each visit Target HbA1c < 53mmol/mol
Prescribing of Hypoglycaemic Agents for Adult Patients with Type 2 Diabetes: Sunderland Refer to DESMOND Structured Education classes to promote Increased Physical Activity, Weight Loss and Calories Reduction
More informationDrug Class Review Newer Diabetes Medications and Combinations
Drug Class Review Newer Diabetes Medications and Combinations Final Update 2 Report July 2016 The purpose reports is to make available information regarding the comparative clinical effectiveness and harms
More informationMaking Sense of Mediations for Diabetes
Making Sense of Mediations for Diabetes Lisa Kroon, PharmD, CDE Professor of Clinical Pharmacy UCSF School of Pharmacy Diabetes Mellitus: U.S. Impact Source: ADA; released June 10, 2014 ~1-1.5 Million
More informationAge-adjusted Percentage of U.S. Adults Who Were Obese or Who Had Diagnosed Diabetes
Age-adjusted Percentage of U.S. Adults Who Were Obese or Who Had Diagnosed Diabetes Obesity (BMI 30 kg/m 2 ) 1994 2000 2009 No Data 26.0% Diabetes 1994 2000 2009
More informationDipeptidyl-Peptidase 4 (DPP-4) Inhibitors Drug Class Prior Authorization Protocol
Dipeptidyl-Peptidase 4 (DPP-4) Inhibitors Drug Class Prior Authorization Protocol Line of Business: Medicaid P&T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed
More informationShould Psychiatrists be diagnosing (and treating) metabolic syndrome
Should Psychiatrists be diagnosing (and treating) metabolic syndrome David Hopkins Clinical Director, Diabetes King s College Hospital, London Diabetes prevalence (thousands) Diabetes in the UK: 1995-2010
More informationPharmacology Updates. Quang T Nguyen, FACP, FACE, FTOS 11/18/17
Pharmacology Updates Quang T Nguyen, FACP, FACE, FTOS 11/18/17 14 Classes of Drugs Available for the Treatment of Type 2 DM in the USA ### Class A1c Reduction Hypoglycemia Weight Change Dosing (times/day)
More informationThe Many Faces of T2DM in Long-term Care Facilities
The Many Faces of T2DM in Long-term Care Facilities Question #1 Which of the following is a risk factor for increased hypoglycemia in older patients that may suggest the need to relax hyperglycemia treatment
More informationAgenda. Indications Different insulin preparations Insulin initiation Insulin intensification
Insulin Therapy F. Hosseinpanah Obesity Research Center Research Institute for Endocrine sciences Shahid Beheshti University of Medical Sciences November 11, 2017 Agenda Indications Different insulin preparations
More informationNew Antidiabetic Medications
New Antidiabetic Medications A/Prof Harvey Newnham Director of General Medicine Clinical Program Director Emergency and Acute Medicine, Alfred Health, Melbourne 5 th May 2013 Diagnosed Diabetes USA Adults
More informationJonathan Stoehr, MD PhD Endocrinology, Diabetes, Metabolism and Nutrition Virginia Mason Medical Center Seattle, WA 2012 Virginia Mason Medical
Jonathan Stoehr, MD PhD Endocrinology, Diabetes, Metabolism and Nutrition Virginia Mason Medical Center Seattle, WA There is no conflict of interest that could be perceived as prejudicing the impartiality
More informationDiabetes Management: A diagnostic perspective
Diabetes Management: A diagnostic perspective Images: http://www.engadget.com/2009/09/23/bayer-introduces-countour-usb-glucose-meter/ http://www.medtronicdiabetes.com/treatment-and-products/minimed-530g-diabetes-system-with-enlite
More informationNew York State Medicaid Prescriber Education Program
New York State Medicaid Prescriber Education Program Metformin as a first-line medication Treating type 2 diabetes mellitus Key messages 1) Metformin should be used as a first-line medication in almost
More informationCAMBRIDGESHIRE JOINT PRESCRIBING GROUP DECISION DOCUMENT Recommendation made by CJPG to Commissioners and Prescribers
CAMBRIDGESHIRE JOINT PRESCRIBING GROUP DECISION DOCUMENT Recommendation made by CJPG to Commissioners and Prescribers Linagliptin (Trajenta, Boehringer Ingelheim Ltd) for the treatment of type 2 diabetes
More informationIncretin-based Therapies for Type 2 Diabetes Comparisons Between Glucagon-like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors
Incretin-based Therapies for Type 2 Diabetes Comparisons Between Glucagon-like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors Timothy Bailey, MD, FACE, CPI Director, AMCR Institute,
More informationManagement of diabetics with advanced CKD
Management of diabetics with advanced CKD JAMES HEAF UNIVERSITY OF COPENHAGEN HERLEV HOSPITAL heaf@dadlnet.dk Antidiabetic Drugs CKD and Glycaemic Control Kovesdy AJKD 52:766 2008 CKD and Glycaemic Control
More informationNew Therapies for Diabetes
Type 2 diabetes is increasingly prevalent New Therapies for Diabetes Lynn Mack, M.D. Associate Professor Diabetes, Endocrinology, & Metabolism The Nebraska Medical Center lmack@unmc.edu No Conflicts of
More informationAnti-Diabetic. Endocrine gland that produces the peptide hormones insulin, glucagon, somatostatin. Exocrine gland that produces digestive enzymes.
Anti-Diabetic The pancreas : Endocrine gland that produces the peptide hormones insulin, glucagon, somatostatin Exocrine gland that produces digestive enzymes. The peptide hormones are secreted from cells
More informationProfessor Rudy Bilous James Cook University Hospital
Professor Rudy Bilous James Cook University Hospital Rate per 100 patient years Rate per 100 patient years 16 Risk of retinopathy progression 16 Risk of developing microalbuminuria 12 12 8 8 4 0 0 5 6
More informationsitagliptin, 25mg, 50mg and 100mg film-coated tablets (Januvia ) SMC No. (1083/15) Merck Sharp and Dohme UK Ltd
sitagliptin, 25mg, 50mg and 100mg film-coated tablets (Januvia ) SMC No. (1083/15) Merck Sharp and Dohme UK Ltd 07 August 2015 The Scottish Medicines Consortium (SMC) has completed its assessment of the
More information9/29/ Disclosure. Learning Objectives. Diabetes Update: Guidelines, Treatment Options & Trends
+ Diabetes Update: Guidelines, Treatment Options & Trends Melissa Max, PharmD, BC-ADM, CDE Assistant Professor of Pharmacy Practice Harding University College of Pharmacy + Disclosure Conflicts Of Interest
More informationDiabetes 2013: Achieving Goals Through Comprehensive Treatment. Session 2: Individualizing Therapy
Diabetes 2013: Achieving Goals Through Comprehensive Treatment Session 2: Individualizing Therapy Joshua L. Cohen, M.D., F.A.C.P. Professor of Medicine Interim Director, Division of Endocrinology & Metabolism
More informationGLP-1 (glucagon-like peptide-1) Agonists (Byetta, Bydureon, Tanzeum, Trulicity, Victoza ) Step Therapy and Quantity Limit Criteria Program Summary
OBJECTIVE The intent of the GLP-1 (glucagon-like peptide-1) s (Byetta/exenatide, Bydureon/ exenatide extended-release, Tanzeum/albiglutide, Trulicity/dulaglutide, and Victoza/liraglutide) Step Therapy
More informationEndo 2 SLO Practice (online) Page 1 of 7
Endo 2 SLO Practice (online) Page 1 of 7 1. A long- acting insulin, like Lantus is for? A. When the next meal is within 30-60 minutes of the injection B. Over night use or for ½ of the day often combined
More informationScottish Medicines Consortium
Scottish Medicines Consortium liraglutide 6mg/mL prefilled pen for injection (3mL) (Victoza ) Novo Nordisk Ltd. No. (585/09) 06 November 2009 The Scottish Medicines Consortium (SMC) has completed its assessment
More informationGlyceamic control is indicated by 1. Fasting blood sugar less than 126 mg/dl 2. Random blood sugar 3. HbA1c less than 6.5 % Good glycaemic control
Glyceamic control is indicated by 1. Fasting blood sugar less than 126 mg/dl 2. Random blood sugar 3. HbA1c less than 6.5 % Good glycaemic control can prevent many of early type 1 DM(in DCCT trail ). UK
More informationOral Hypoglycemics and Risk of Adverse Cardiac Events: A Summary of the Controversy
Oral Hypoglycemics and Risk of Adverse Cardiac Events: A Summary of the Controversy Jeffrey Boord, MD, MPH Advances in Cardiovascular Medicine Kingston, Jamaica December 7, 2012 VanderbiltHeart.com Outline
More information